Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20020 (
adenosine triphosphatase
)
3,299
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
1. P-glycoprotein, a 170-180 kDa
membrane glycoprotein
that mediates multidrug resistance, hydrolyses ATP to efflux a broad spectrum of hydrophobic agents. In this study, we analysed the effects of three MDR reversing agents, verapamil, cyclosporin A and [3'-keto-Bmt1]-[Val2]-cyclosporin (PSC 833), on the
adenosine triphosphatase
(
ATPase
) activity of human P-glycoprotein. 2. P-glycoprotein was immunoprecipitated with a monoclonal antibody (MRK-16) and the P-glycoprotein-MRK-16-Protein A-Sepharose complexes obtained were subjected to a coupled enzyme
ATPase
assay. 3. While verapamil activated the
ATPase
, the cyclosporin derivatives inhibited both the substrate-stimulated and the basal P-glycoprotein
ATPase
. No significant difference was observed between PSC 833 and cyclosporin A on the inhibition of basal P-glycoprotein
ATPase
activity. PSC 833 was more potent than cyclosporin A for the substrate-stimulated activity. 4. Kinetic analysis indicated a competitive inhibition of verapamil-stimulated
ATPase
by PSC 833. 5. The binding of 8-azido-[alpha-32P]-ATP to P-glycoprotein was not altered by the cyclosporin derivatives, verapamil, vinblastine and doxorubicin, suggesting that the modulation by these agents of P-glycoprotein
ATPase
cannot be attributed to an effect on ATP binding to P-glycoprotein. 6. The interaction of the cyclosporin derivatives with
ATPase
of P-glycoprotein might present an alternative and/or additional mechanism of action for the modulation of P-glycoprotein function.
...
PMID:Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. 931 31
P-Glycoprotein, a 170-180 kDa
membrane glycoprotein
that mediates multidrug resistance, hydrolyses ATP to efflux a broad spectrum of hydrophobic agents. To observe the interaction of a P-gp reversal agent with P-gp
ATPase
activity should provide further insights into the mechanisms of P-gp modulator. In this study, we analysed the effect of CJZ3, a lomerizine derivative, on the
adenosine triphosphatase
(
ATPase
) activity of human P-glycoprotein. The results showed that the basal P-gp
ATPase
activity was increased by CJZ3 with half-maximal activity concentration (Km) of 6.8 +/- 1.5 microM, CJZ3 may interact with P-gp with a higher affinity and exhibit a more potent effect than verapamil (Ver). Kinetic analysis indicated a noncompetitive inhibition of Ver-stimulated P-gp
ATPase
activity and a competitive inhibition of CJX2-stimulated P-gp
ATPase
activity by CJZ3, moreover, the effect of CsA on CJZ3-stimulated and Ver-stimulated P-gp
ATPase
activity showed a non-competitive and a competitive inhibition respectively. CJZ3 and CJX2 can bind P-gp either on overlapping sites or distinct but interacting sites, while CJZ3 and Ver as well as CsA can bind P-gp on separated sites in K562/DOX cells.
...
PMID:Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. 2066 21